Pirepemat

DB19165InvestigationalSmall molecule

Pirepemat is under investigation in clinical trial NCT05258071 (A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease (PD)).

Formula / weight: C₁₁H₁₃F₂NO · 213.228 g/mol (avg)
Also known as: (3s)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine · Pyrrolidine, 3-(2,3-difluorophenyl)-3-methoxy-, (+)- · Pyrrolidine, 3-(2,3-difluorophenyl)-3-methoxy-, (3s)-
Code names: IRL-752

Resolves to

Compound

UNIIJS88RK5NOICAS1227638-29-0ChEMBLCHEMBL5095193

Structure

InChIKeyLJNFYMMXCXGFCP-LLVKDONJSA-NSMILESCO[C@@]1(CCNC1)C1=CC=CC(F)=C1F

What you can answer from here — as of July 06, 2024

1Clinical trialPhase, status and sponsor resolved per trial

Which companies are running trials of Pirepemat, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account